Organon (OGN) Total Liabilities (2020 - 2026)
Organon (OGN) posted quarterly Total Liabilities of $12.1 billion for Q1 2026, down 4.13% year-over-year from $12.6 billion in Q1 2025, and little changed on a QoQ basis from $12.1 billion in Q4 2025.
Organon (OGN) Total Liabilities (2020 - 2026) Analysis & Trends
Organon (OGN) has reported Total Liabilities for 7 consecutive years, with $12.1 billion the latest figure, recorded in Q1 2026.
- In Q1 2026, Total Liabilities fell 4.13% year-over-year to $12.1 billion; the TTM figure through Mar 2026 stood at $12.1 billion (down 4.13% YoY), while the FY2025 annual figure was $12.1 billion, down 4.07% from the prior year.
- Total Liabilities came in at $12.1 billion for Q1 2026 at Organon, roughly flat from $12.1 billion in the prior quarter.
- The five-year high for Total Liabilities was $12.8 billion in Q2 2025, with the low at $11.5 billion in Q1 2023.
- Average Total Liabilities over 5 years is $12.0 billion, with a median of $12.0 billion recorded in 2024.
- The largest YoY upside for Total Liabilities was 140.79% in 2022 against a maximum downside of 11.19% in 2022.
- Year by year, Total Liabilities stood at $11.8 billion in 2022, then gained by 2.37% to $12.1 billion in 2023, then increased by 4.13% to $12.6 billion in 2024, then declined by 4.07% to $12.1 billion in 2025, then retreated by 0.18% to $12.1 billion in 2026.
- According to Business Quant data, Total Liabilities over the past three periods registered $12.1 billion, $12.1 billion, and $12.6 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Eli Lilly | 1,066.16 Bn | 1,060.88 Bn | 16.22 Bn | 85.38 Bn |
| 2 | Johnson & Johnson | 611.69 Bn | 589.64 Bn | 15.96 Bn | 119.71 Bn |
| 3 | AbbVie | 444.34 Bn | 434.99 Bn | 10.78 Bn | 143.12 Bn |
| 4 | Astrazeneca | 284.94 Bn | 277.05 Bn | 12.61 Bn | -66.63 Bn |
| 5 | Merck | 224.23 Bn | 218.58 Bn | 12.09 Bn | 82.81 Bn |
| 6 | Amgen | 195.12 Bn | 183.08 Bn | 5.87 Bn | 83.31 Bn |
| 7 | Gilead Sciences | 156.45 Bn | 148.73 Bn | 5.52 Bn | 32.76 Bn |
| 8 | Pfizer | 136.01 Bn | 123.24 Bn | -1.21 Bn | 117.21 Bn |
| 9 | Novartis Ag | 113.45 Bn | 113.67 Bn | - | - |
| 10 | Organon | 3.53 Bn | 2.41 Bn | 783.00 Mn | 12.09 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.09 Bn |
| Dec 31, 2025 | 12.12 Bn |
| Sep 30, 2025 | 12.65 Bn |
| Jun 30, 2025 | 12.77 Bn |
| Mar 31, 2025 | 12.61 Bn |
| Dec 31, 2024 | 12.63 Bn |
| Sep 30, 2024 | 12.26 Bn |
| Jun 30, 2024 | 12.01 Bn |
| Mar 31, 2024 | 11.84 Bn |
| Dec 31, 2023 | 12.13 Bn |
| Sep 30, 2023 | 11.60 Bn |
| Jun 30, 2023 | 11.53 Bn |
| Mar 31, 2023 | 11.50 Bn |
| Dec 31, 2022 | 11.85 Bn |
| Sep 30, 2022 | 11.50 Bn |
| Jun 30, 2022 | 11.75 Bn |
| Mar 31, 2022 | 11.85 Bn |
| Dec 31, 2021 | 12.19 Bn |
| Sep 30, 2021 | 12.95 Bn |
| Jun 30, 2021 | 12.84 Bn |